| Acceptance rate | 46% |
|---|---|
| Time to first decision | 6 months* |
| Time to decision with review | 50 days* |
*Approximate number of days
**The days mentioned above are averages and do not indicate exact durations. The process may vary for each article.
ACTA Pharmaceutica Sciencia
2024 , Vol 62 , Num 1
Levels of adiponectin, malondialdehyde and lipid profile in women with polycystic ovary syndrome
1 University of Mosul, College of Pharmacy, Department of Pharmacognosy and Medicinal Plants, Mosul, IraqDOI : 10.23893/1307-2080.APS6203 Viewed : 2144 - Downloaded : 726 Polycystic ovary syndrome (PCOS) is a heterogeneous disease affects about 4-18% of women of reproductive age worldwide, with associated increased risk of endocrine, metabolic, and reproductive defects. Adiponectin (ADP), the most abundantly secreted adipokine, is a homeostatic regulating factor for insulin, lipid, and glucose through its antioxidant, anti-fibrotic, and anti-inflammatory effects. Serum levels of adiponectin, malondialdehyde (MDA), and lipid profile were evaluated in the fasting sample in 30 healthy underweight women as a control group, and 30 females with PCOS, age, and body mass index (BMI) matched with the healthy control. Compared with the healthy control, serum levels of adiponectin were significantly lower in females with PCOS. Additionally, total cholesterol (TC) levels were significantly higher in concomitant women compared to the control group. Interestingly, no significant variations were observed in the serum levels of MDA, LDL, TG, VLDL, and HDL. However, no significant correlations were found between the study groups. In conclusion, findings of our study revealed that low adiponectin and high total cholesterol levels could serve as predictive markers of PCOS risk in lean women with a family history of PCOS, or women with fewer symptoms. Keywords : PCOS, lipids, malondialdehyde, adiponectin, BMI